New study conducted by Inmunotek together with ClinCompetence Cologne promising results for short-course of subcutaneous treatment

11. December 2024 | Publication

A recent study published in the journal Allergy has shown that a short course of allergy shots can significantly reduce symptoms and medication use in people with birch pollen allergy. The study involved 298 adults with birch pollen allergy who were given either a...

EAACI Congress 2024, Valencia (Spain), 31 May – 03 June 2024

29. May 2024 | Publication

Saturday, June 1st 12:00 am | Together with Bencard Germany ClinCompetence Cologne presents an interim analysis of a 5 years AIT cohort study in Children, adolescents and adults TAPAS – a long-term non-interventional study evaluating MCT (MicroCrystalline...

A high-dose, depigmented polymerized birch pollen extract for subcutaneous allergen immunotherapy has a favourable efficacy/safety ratio

29. January 2024 | Publication

Oliver Pfaar1, Angelika Sager2, Ralph Mösges34, Margitta Worm5 Affiliations Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany. ↩︎ LETI Pharma...

EAACI 2023 Hamburg, Germany: Together with Inmunotek, Madrid, Spain, ClinCompetence Cologne present the complete results of the betMan development program in birch pollen-induced rhinoconjunctivitis. 

9. June 2023 | Publication

Clinical Development of Mannan conjugated birch pollen allergoids for the treatment of birch pollen allergic patients – from first-in-human to clinical validation in 3 studies

16. March 2023 | Publication

Affiliations Ralph Mösges, PhD, MD FAAAAI Esther Raskopf, PhD Silke Allekotte, PhD Mandy Cuevas, MD Enrique Fernandez-Caldas, PhD José. L. Subiza, MD, PhD Miguel Casanovas, MD, PhD Rationale The aim of a drug development program for allergen immunotherapies is to get...